Aurinia Pharmaceuticals Inc. (AUPH) Financial Ratios
28 years of historical data (1998–2025) · Healthcare · Biotechnology
EV/EBITDA
↓
20.44
↓-63% vs avg
5yr avg: 54.86
30Y Low21.0·High88.7
P/FCF
↓
15.88
↓-31% vs avg
5yr avg: 23.05
30Y Low16.3·High29.8
P/B Ratio
↓
3.88
+5% vs avg
5yr avg: 3.68
30Y Low1.5·High6.3
ROE
↑
59.9%
↓+1361% vs avg
5yr avg: -4.8%
30Y Low-454%·High60%
Debt/EBITDA
↓
0.71
↓-77% vs avg
5yr avg: 3.05
30Y Low0.7·High5.4
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
AUPH Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Aurinia Pharmaceuticals Inc. trades at 7.8x earnings, 93% below its 5-year average of 118.1x, sitting at the 100th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.2x, the stock trades at a discount of 65%. On a free-cash-flow basis, the stock trades at 15.9x P/FCF, 31% below the 5-year average of 23.1x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $2.1B | $2.2B | $1.3B | $1.3B | $613M | $3.0B | $1.6B | $1.9B | $578M | $349M | $74M |
| Enterprise Value | $2.1B | $2.2B | $1.3B | $1.3B | $527M | $2.7B | $1.4B | $1.6B | $460M | $183M | $34M |
| P/E Ratio → | 7.85 | 7.71 | 228.50 | — | — | — | — | — | — | — | — |
| P/S Ratio | 7.59 | 7.82 | 5.58 | 7.34 | 4.57 | 64.88 | 32.69 | 5926.62 | 1248.84 | 829.94 | 428.32 |
| P/B Ratio | 3.88 | 3.81 | 3.48 | 3.41 | 1.51 | 6.18 | 4.02 | 6.31 | 5.14 | 2.10 | 2.06 |
| P/FCF | 15.88 | 16.34 | 29.76 | — | — | — | — | — | — | — | — |
| P/OCF | 15.85 | 16.31 | 29.58 | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
AUPH EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Aurinia Pharmaceuticals Inc.'s enterprise value stands at 20.4x EBITDA, 63% below its 5-year average of 54.9x. The Healthcare sector median is 14.1x, placing the stock at a 45% premium on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 7.80 | 5.57 | 7.61 | 3.93 | 59.98 | 27.43 | 4964.30 | 994.05 | 435.58 | 199.13 |
| EV / EBITDA | 20.44 | 21.03 | 88.68 | — | — | — | — | — | — | — | — |
| EV / EBIT | 20.44 | — | 106.55 | — | — | — | — | — | — | — | — |
| EV / FCF | — | 16.30 | 29.67 | — | — | — | — | — | — | — | — |
AUPH Profitability
Margins and return-on-capital ratios measuring operating efficiency
Aurinia Pharmaceuticals Inc. earns an operating margin of 37.1%. Operating margins have expanded from -52.2% to 37.1% over the past 3 years, signaling improving operational efficiency. Return on equity of 59.9% is exceptionally high. ROIC of 16.6% represents solid returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 88.5% | 88.5% | 88.0% | 91.9% | 95.8% | 97.6% | 100.0% | 100.0% | -8837.8% | 99.8% | 97.7% |
| Operating Margin | 37.1% | 37.1% | -2.0% | -52.2% | -83.2% | -396.3% | -208.1% | -28598.4% | -12129.2% | -11205.5% | -13187.3% |
| Net Profit Margin | 101.5% | 101.5% | 2.4% | -44.5% | -80.7% | -396.8% | -204.9% | -27794.0% | -13848.8% | -16855.2% | -13465.3% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 59.9% | 59.9% | 1.5% | -19.9% | -24.5% | -40.8% | -29.1% | -43.0% | -46.1% | -70.2% | -83.3% |
| ROA | 44.1% | 44.1% | 1.0% | -15.3% | -21.3% | -35.9% | -26.1% | -37.6% | -38.2% | -57.4% | -51.4% |
| ROIC | 16.6% | 16.6% | -0.9% | -18.4% | -29.1% | -67.8% | -114.7% | — | — | — | -325.7% |
| ROCE | 18.9% | 18.9% | -1.0% | -20.5% | -24.0% | -38.7% | -28.0% | -40.3% | -35.1% | -40.8% | -57.7% |
AUPH Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Aurinia Pharmaceuticals Inc. carries a Debt/EBITDA ratio of 0.7x, which is very conservative (77% below the sector average of 3.1x). The company holds a net cash position — cash of $80M exceeds total debt of $75M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.13 | 0.13 | 0.21 | 0.26 | 0.02 | 0.02 | 0.02 | — | — | — | — |
| Debt / EBITDA | 0.71 | 0.71 | 5.38 | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.01 | -0.01 | 0.13 | -0.21 | -0.47 | -0.65 | -1.02 | -1.05 | -1.00 | -1.10 |
| Net Debt / EBITDA | -0.05 | -0.05 | -0.28 | — | — | — | — | — | — | — | — |
| Debt / FCF | — | -0.04 | -0.09 | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | -0.97 | -33.04 | — | — | — | — | — | — | — |
Net cash position: cash ($80M) exceeds total debt ($75M)
AUPH Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Aurinia Pharmaceuticals Inc.'s current ratio of 5.25x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 4.76x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has declined from 5.50x to 5.25x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.25 | 5.25 | 4.57 | 5.50 | 9.60 | 12.63 | 13.11 | 27.90 | 18.30 | 21.50 | 5.22 |
| Quick Ratio | 4.76 | 4.76 | 4.17 | 4.99 | 9.06 | 12.15 | 12.67 | 27.90 | 18.30 | 21.52 | 5.22 |
| Cash Ratio | 4.25 | 4.25 | 3.67 | 4.54 | 8.45 | 11.47 | 12.45 | 27.09 | 17.33 | 21.28 | 5.00 |
| Asset Turnover | — | 0.38 | 0.43 | 0.32 | 0.28 | 0.08 | 0.11 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.71 | 0.71 | 0.72 | 0.36 | 0.23 | 0.06 | — | — | — | — | — |
| Days Sales Outstanding | — | 53.45 | 56.73 | 50.10 | 36.72 | 123.37 | — | 422.39 | 171.07 | 94.73 | 181.45 |
AUPH Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Aurinia Pharmaceuticals Inc. returns 4.6% to shareholders annually primarily through share buybacks. The earnings yield of 12.7% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 12.7% | 13.0% | 0.4% | — | — | — | — | — | — | — | — |
| FCF Yield | 6.3% | 6.1% | 3.4% | — | — | — | — | — | — | — | — |
| Buyback Yield | 4.6% | 4.4% | 3.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 4.6% | 4.4% | 3.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $139M | $146M | $143M | $142M | $129M | $118M | $93M | $85M | $77M | $35M |
Peer Comparison
Compare AUPH with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 AUPHYou | $2B | 7.8 | 20.4 | 15.9 | 88.5% | 37.1% | 59.9% | 16.6% | 0.7 |
 LGND | $5B | -1057.0 | 356.7 | 59.1 | 93.4% | -13.5% | -0.5% | -2.3% | 0.6 |
 ANIP | $2B | 25.3 | 9.0 | 9.6 | — | 12.6% | 16.2% | 11.2% | 1.6 |
 PRAX | $8B | -25.1 | — | — | — | — | -45.8% | -65.0% | — |
 CORT | $6B | 63.6 | 117.5 | 39.5 | 98.3% | 5.9% | 15.0% | 6.2% | 0.1 |
 GSK | $102B | 6.7 | 8.4 | 12.8 | 72.4% | 25.5% | 39.4% | 22.1% | 1.7 |
 BIIB | $28B | 21.6 | 11.4 | 13.7 | 70.5% | 19.1% | 7.4% | 6.5% | 2.5 |
 ALNY | $40B | 130.0 | 71.9 | 86.9 | 81.8% | 13.5% | 73.3% | 33.4% | 2.3 |
 VKTX | $4B | -10.1 | — | — | — | — | -47.3% | -44.4% | — |
 IQV | $30B | 22.5 | 12.9 | 14.6 | 26.3% | 14.0% | 21.4% | 8.7% | 4.7 |
 CRL | $9B | -62.5 | 13.0 | 17.3 | 30.5% | 12.6% | -4.3% | 6.3% | 3.4 |
| Healthcare Median | — | 22.2 | 14.1 | 18.6 | 64.1% | -5.3% | -34.0% | -11.2% | 3.1 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 28 years · Updated daily
See AUPH's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs AUPH Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare AUPH vs LGND
Side-by-side business, growth, and profitability comparison vs Ligand Pharmaceuticals Incorporated.
Start ComparisonAUPH — Frequently Asked Questions
Quick answers to the most common questions about buying AUPH stock.
What is Aurinia Pharmaceuticals Inc.'s P/E ratio?
Aurinia Pharmaceuticals Inc.'s current P/E ratio is 7.8x. The historical average is 7.7x. This places it at the 100th percentile of its historical range.
What is Aurinia Pharmaceuticals Inc.'s EV/EBITDA?
Aurinia Pharmaceuticals Inc.'s current EV/EBITDA is 20.4x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 54.9x.
What is Aurinia Pharmaceuticals Inc.'s ROE?
Aurinia Pharmaceuticals Inc.'s return on equity (ROE) is 59.9%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is -65.6%.
Is AUPH stock overvalued?
Based on historical data, Aurinia Pharmaceuticals Inc. is trading at a P/E of 7.8x. This is at the 100th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Aurinia Pharmaceuticals Inc.'s profit margins?
Aurinia Pharmaceuticals Inc. has 88.5% gross margin and 37.1% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
How much debt does Aurinia Pharmaceuticals Inc. have?
Aurinia Pharmaceuticals Inc.'s Debt/EBITDA ratio is 0.7x, indicating low leverage. A ratio below 2x is generally considered financially healthy.